Search

everythinglearnresearchcommunity

for

Search:↓

A 20 year old male who is balding and considering switching to a biology/chemistry program in order to find a low-cost, accessible solution for hair loss. Replies discuss the merits of this idea as well as potential treatments such as Minoxidil, finasteride, RU58841, TM5614, and ADQ.

A user's progress using minoxidil and dutasteride mesotherapy to treat hair loss, with advice from other users on whether or not to continue the treatment. Suggestions included trying oral treatments such as finasteride and RU58841, and considering a hair transplant for more significant results.

. This user experienced positive results from using a combination of minoxidil and finasteride, with no reported side effects after two months. Others have also shared their experiences with both short-term and long-term use of finasteride.

Hair loss treatments discussed include Minoxidil, Finasteride, RU58841, ass hair transplant, topical Viagra, castration, and transitioning to female. A user mentions an experimental drug called M4U-5 (Mousteride) that turns you into a mouse.

A user noticed wrinkling under one eye, possibly due to Minoxidil use. They seek advice on preventing or fixing this issue.

Stopping finasteride increased sex drive for some, while others had no change or different side effects. Despite concerns, many continue using finasteride for its effectiveness in preventing hair loss.

A user added sandalore to minoxidil for hair loss, observing some vellus hair growth and less scalp inflammation. Others tried sandalore with mixed results, discussing dosage and effectiveness compared to minoxidil and finasteride.

The conversation discusses the effects of finasteride on libido, with the original poster experiencing a significant decrease in sexual desire after starting the medication. Other users share similar experiences and suggest potential remedies, including Vitamin E supplementation and lifestyle changes like avoiding pornography.

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

A user shared a natural hair loss treatment involving micro-needling and a mix of turmeric, cinnamon, and coconut oil, claiming it effectively thickened their hair. The treatment is applied every two to three weeks, but some users expressed skepticism and requested photographic evidence.

The efficacy of microneedling for hair regrowth as either a stand-alone therapy or adjunct to Minoxidil, and whether Tretinoin is a safer and more effective option. Replies include personal accounts from users who have had success with microneedling in combination with minoxidil and peptide serums, as well as considerations of technique, depth, and potential scarring.

A user's experience with Pyrilutamide for hair loss, which has been successful in reversing receding hairline when part of their stack with other treatments such as Dutasteride, Minoxidil, and Ketoconazole shampoo.

The user reversed male pattern baldness using a pro-thyroid diet, lifestyle changes, and scalp stimulation exercises, without Minoxidil or Finasteride. They reported reduced dandruff, itchiness, oiliness, and experienced hair regrowth and thickening over 15 months.

The conversation discusses using RU58841, a research chemical, for hair loss treatment. The user plans to use it due to side effects from finasteride and minoxidil, despite skepticism about its effectiveness and lack of FDA approval.

Topical finasteride may have higher systemic absorption and lower efficacy when using a Propylene Glycol/Ethanol formulation compared to the hydroxypropyl chitosan (HPCH) formulation. The safety profile of topical finasteride relies heavily on the HPCH formulation, and using standard solutions might lead to different pharmacokinetics.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The conversation discusses the variability in effectiveness of medications, including finasteride, and questions whether different manufacturers impact results. The user suggests sharing successful brands to help others identify effective options.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

The conversation is about the stability of pyrilutamide in different solutions. The user is asking if a 70/30 ethanol/pg solution with 4% water will degrade pyrilutamide.

User decides to accept baldness due to mental health issues with finasteride. Others suggest considering hair systems, topical finasteride, or RU58841 as alternatives.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The user noticed a slight loss of progress after switching to Milpharm finasteride 1mg and is considering switching to Accord finasteride. They seek advice on whether to continue with Milpharm or switch brands.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

Belgium disagrees with the EMA and does not authorize the 1 mg oral form of finasteride for androgenic alopecia, citing a negative benefit-risk ratio. Despite this, some individuals in Belgium can still obtain finasteride through prescriptions, and there is debate over its mental health risks versus its benefits for hair loss and other health issues.

A user was embarrassed by a pharmacist's loud mention of "minoxidil" for hair loss, sparking a discussion on the stigma and unprofessionalism. Users suggested online purchases or different pharmacies for privacy and reassured that most people don't notice others' purchases.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.

The user noticed slight hair loss after switching to Milpharm finasteride and is considering switching to Accord finasteride. They seek advice on whether to continue with Milpharm or switch brands.